Xenetic Biosciences issues 850,000 shares to CLS Therapeutics for patent rights

Xenetic Biosciences, Inc.

Issued 850,000 common shares to CLS Therapeutics LLC as consideration for assignment of certain patent rights.
Transaction closed on October 12, 2022; shares unregistered and sold under Section 4(a)(2) and Regulation D.
CLS represented itself as an accredited investor; shares restricted and not registered under Securities Act.
No other securities or cash consideration disclosed; shares issued directly for patent asset acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.